Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic controlled trial of NZT-235
jRCT2071200116Phase 1Completed
- Sponsor
- Nippon Zoki Pharmaceutical
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NZT-235 in postherpetic neuralgia (PHN), sponsored by Nippon Zoki Pharmaceutical. Primary endpoint: Plasma NZT-235 concentration. Started Apr 2021; status: completed.
02
Drugs
NZT-235
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on jRCT2071200116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200116.